9MW1411 + linezolid

**9MW1411 + linezolid** is an investigational combination therapy studied for the treatment of acute bacterial skin and skin structure infections (ABSSSI), primarily those caused by *Staphylococcus aureus*. 9MW1411 is a recombinant humanized monoclonal antibody that targets and neutralizes *Staphylococcus aureus* α-toxin, a key virulence factor in infection. Linezolid is a well-established oxazolidinone class antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The rationale for combining these drugs is to target both the bacterial agent (with linezolid) and its toxin-mediated pathology (with 9MW1411), potentially increasing clinical cure rates. The combination is delivered via intravenous infusion and is currently studied in Phase II clinical trials[1][2][3].